Clinical Trial Update: Study on BI 54903 (Inhaled Corticosteroid) Administered Once Daily or Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Low Dose Inhaled Corticosteroids [Phase 2]

View source ↗

Summary

A Phase 2 study of BI 54903, an inhaled corticosteroid, for asthma that was inadequately controlled on low-dose inhaled corticosteroids has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• BI 54903

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Asthma | Phase 2 | Status: WITHDRAWN